In order to gather both qualitative and quantitative insights, supply-side and demand-side stakeholders were interviewed during the primary research process. CEOs, VPs of R&D, heads of Genomics Product Development, heads of regulatory affairs, and commercial directors from NGS platform makers, sample preparation kit suppliers, and automation system OEMs were examples of supply-side sources. Clinical laboratory directors, genomic scientists, bioinformatics leads, research institute principal investigators, and procurement managers from academic research centers, clinical diagnostic labs, pharmaceutical R&D facilities, and hospital-based genomics centers were among the demand-side sources. Primary research verified product development pipelines for automated sample prep systems, validated market segmentation across workflow steps (DNA extraction, RNA extraction, library preparation, target enrichment), and gathered information on clinical adoption of NGS in oncology and rare disease diagnostics, pricing strategies for consumables vs. instruments, and reimbursement dynamics for NGS-based testing.
Primary Respondent Breakdown:
By Designation: C-level Primaries (32%), Director Level (31%), Others (37%)
By Region: North America (32%), Europe (30%), Asia-Pacific (33%), Rest of World (5%)
Global market valuation was derived through revenue mapping and installed base analysis. The methodology included:
Identification of 50+ key manufacturers across North America, Europe, Asia-Pacific, and Latin America specializing in nucleic acid extraction, library preparation, and target enrichment solutions
Product mapping across DNA extraction kits, RNA extraction kits, library preparation reagents, target enrichment panels, and automated sample preparation workstations
Analysis of reported and modeled annual revenues specific to NGS sample preparation portfolios (excluding sequencing instrument revenues)
Coverage of manufacturers representing 75-80% of global market share in 2024
Extrapolation using bottom-up (installed base × annual consumables spend by segment) and top-down (manufacturer revenue validation) approaches to derive segment-specific valuations for research applications, clinical diagnostics, and pharmaceutical development